Elutia Inc
Severe listing-compliance risk
The share price is below $1 and the stored reverse-split/listing-risk level is HIGH. No verified reverse-split authorization or announced reverse split is currently recorded. This is a risk signal, not confirmation that Nasdaq has issued a deficiency notice.
ELUT · Price history
Price at last available close
$0.84
+$0.05 (+6.45%) 1M
2026-10-28
Tap or drag sideways to inspect a price. Use two fingers to compare automatically. Release to scroll. Use Shift + arrow keys to compare with a keyboard.
Company & revenue
About Elutia Inc
Primary reporting period: 2025-12-31 · Research updated Oct 13, 2026. A research update is not a new financial filing.
Who they are
Elutia Inc., a commercial-stage company, focuses on developing drug-eluting biomatrix products for use in surgical reconstruction and related applications. The company operates in two segments, Women’s Health and Cardiovascular. Its lead development programs include NXT-41 and NXT-41x, which are designed as biologic scaffolds combined with local antibiotic delivery.
How they make money
Elutia develops and markets proprietary drug-eluting biomatrix products designed to improve the interaction between implanted medical devices and patients. The company generates revenue primarily through the direct sale of its biologic matrix products to healthcare facilities, supported by independent sales agents.
Products & services
Proprietary biologic matrix products including SimpliDerm (human acellular dermal matrix for soft tissue reconstruction) and a cardiovascular repair portfolio comprising ProxiCor, VasCure, and Tyke.
Brands & revenue mix
Human acellular dermal matrix used in soft tissue reconstruction.
Separate brand revenue is not available in this research.Source
Cardiovascular repair product.
Separate brand revenue is not available in this research.Source
Cardiovascular repair product.
Separate brand revenue is not available in this research.Source
Revenue share is not unit sales or a best-seller ranking. Parent brands and included sub-brands can overlap; do not add overlapping rows.
Product / operating segments
Geographic revenue
No reconciled geographic revenue breakdown was confirmed for the current research period.
Customer types
- Healthcare facilitiesSource
Customer concentration
No quantified customer-concentration disclosure is available in the current saved research.
Suppliers, materials & equipment
- Independent sales agents — Third-party sales representatives used to distribute products to healthcare facilities.Source
Strengths
- Proprietary drug-eluting biomatrix technology platformSource
Financial risk observations and what to check
These are saved observations about business performance, not predictions. Review the company filings alongside the interpretation below. Latest stored financial period end: 2026-06-30.
Quarterly revenue fell 61.2% versus the same quarter last year.
Check comparable business scope and currency, then separate volume, pricing and divestitures. One weaker quarter does not establish that the same decline will continue.
Wall Street Score
Overall investment score · Quality, value, risk and opportunity
50
Fair
View category scores →
Company Quality
How good is the actual business—regardless of today’s stock price?
43
Weak
Financial Strength
65
Business Quality / Moat
0
Management
80
Growth Quality
43
Risk / Durability
11
Uses financial strength, moat, management, growth quality and durability. It excludes share price, P/E, market cap, intrinsic value and margin of safety.
Opportunity
Opportunity Score · How does the current price compare with estimated value?
69
Fully Valued
Based on current valuation, company quality, recent trends, and available market signals.
View score details →
Model Outlook
12-month model · What does the model think happens next?
59/100
Building Historical Record
Model Score 59/100 — estimates relative performance potential, distinct from the overall Wall Street Score and the separate Company Quality score.
Probability unavailable — the model has not produced a calibrated probability yet.
Click for full breakdown →
Reverse-split / listing-compliance risk: HIGH
This is a risk signal, not a prediction. It is separate from Wall Street Score and does not change the company score. It looks for listing-pressure signals such as prolonged Nasdaq trading below $1, very low share price, micro-cap size, negative free cash flow, and verified recent reverse splits.
Risk indicator: 55/100
WSS View
The quick read
The overall Wall Street Score is mixed across its combined quality, valuation and risk inputs. Review the category scores to identify what is helping or hurting the result.
At today’s price, the WSS valuation framework currently reads as moderate rather than unusually attractive.
The model outlook is currently moderate.
- •Balance-sheet / debt profile scores strongly
- •Asset quality scores strongly
- •Valuation scores attractively
- •Debt service risk
- •M&A headline · Aug 18, 2026
- •Revenue fundamentals are weak
Company-specific research
Questions worth answering for ELUT
These questions are generated from this company's current financial and score data so the page adds context instead of treating the headline score as a stand-alone conclusion.
- •What is driving ELUT's revenue decline, and does the latest company filing suggest the weakness is temporary or structural?
- •How long can ELUT fund negative free cash flow using its current cash position before it may need more debt or new shares?
- •How is ELUT likely to use its cash advantage: reinvestment, acquisitions, debt reduction, dividends or buybacks?
- •Is ELUT's valuation discount tied to a temporary concern or to a longer-term business risk?
- •What does the current fundamental change risk warning mean for the reliability or interpretation of ELUT's score?
Essential Investment Snapshot
Wall Street Score
50
Opportunity Score
69
Market Cap
$37.2M
P/E Ratio
0.6
EPS
$1.30
52-Week High
$1.39
52-Week Low
$0.50
Beta
0.88
Intrinsic Value
$11.06
Analyst Target
$10.00
Shares Outstanding
45.9M
Total Revenue
$12.1M
Total Debt
$10.8M
Dividend
No current dividend
Liquidation Value / Share
$0.34
Momentum & Volatility Signals
Two different market-behavior signals. Momentum measures direction and trend strength. Volatility measures how large and unstable the price moves are, regardless of direction.
Neutral / mixed momentum
Normal movement
A high momentum score means price has been trending upward with confirming short- and medium-term strength. A low score means downward or weakening momentum.
A high volatility score means larger, less stable price swings. It can happen while a stock is rising or falling, so high volatility is not automatically bullish or bearish.
Important: the volatility score above is based on realized price volatility. Implied volatility (IV) comes from options prices and represents the market's expected future movement. Wall Street Score will keep IV separate and will only display it when a verified options-chain feed is available.
Notices for ELUT
Detected from reported data — verify before acting.Debt service risk
Interest coverage is low (~-47.6x). Earnings may be strained to cover interest expense.
M&A headline · Aug 18, 2026
Cellution Biologics Completes Acquisition of SimpliDerm® from Elutia Inc. — This is a provider-linked headline, not an independently confirmed event. Check the article and company filings for the subject, proposed/completed status, and subsequent updates.
GlobeNewsWireCommunity Sentiment
0 active · 0 total callsNo personal call yet on ELUT.
Potential upside factors
- +Growth opportunities may come from revenue expansion, margin improvement, new products, market-share gains, and stronger cash flow.
- +Proprietary drug-eluting biomatrix technology platform.
Potential downside factors
- −Key risks may include competition, margin pressure, debt levels, valuation risk, and changes in demand within the Biotechnology industry.
- −Dependence on independent sales agents for product distribution.
- −Operational risks associated with transition to new headquarters and manufacturing site.
- −Negative free cash flow may increase the need for outside financing and dilution.
These research factors come from saved company research and financial data, not community votes. They are starting points to verify against filings, not buy or sell recommendations.
Create a free account to make a call.
Scores
Click any score for full breakdownWas this stock page easy to understand?
One click helps us improve the research experience. This is not tied to an investment decision.
Score Changes
6 historical score records availablePrevious Score
63
Sep 21, 2026
Change
-12.5
points
Current Score
50
Oct 1, 2026
Category Changes
ELUT decreased 12.5 points because some fundamentals weakened.
Positive Contributors
- + Asset improved by 2.1 points
Projected Score
Projected Score
47
Projected Change
-3.0 points
Preliminary comparable-period financial changes suggest decline of approximately 3.0 points. This is a projected estimate, not the official WallStreetScore.
Price vs. Value
Review model assumptionsThis model estimate is more than three times the share price.
This is a formula-based estimate, not a verified fair value or price target. Check the earnings and growth assumptions.
Stored EPS: $1.30 · Growth assumption: 0.0% · Earnings multiplier: 8.5×.
Current Price
$0.84
Model Intrinsic Value
$11.06
Difference
−$10.22
-92.4% vs IV
Margin of Safety
92.4%
Financial Charts
Revenue
Additional Metrics
Operating Cash Flow
Total Debt
Total Assets
Net Margin %
Free includes 3 annual periods plus available TTM; Premium includes up to 10 annual periods. History depends on available company filings. Swipe the table horizontally to see older periods. A dash means unavailable, not zero.
| Line Item | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | $12.1M | $12.3M | $24.4M | $24.7M | ···· | ···· | ···· | ···· | ···· |
| Cost of Revenue | $5.1M | $5.7M | $13.7M | $13.7M | ···· | ···· | ···· | ···· | ···· |
| Gross Profit | $7.0M | $6.6M | $10.7M | $11.1M | ···· | ···· | ···· | ···· | ···· |
| Research & Development | $6.8M | $4.2M | $3.8M | $4.4M | ···· | ···· | ···· | ···· | ···· |
| SG&A Expenses | $16.9M | $20.8M | $31.2M | $27.2M | ···· | ···· | ···· | ···· | ···· |
| Operating Expenses | $30.6M | $25.0M | $46.4M | $41.6M | ···· | ···· | ···· | ···· | ···· |
| EBITDA | -$24.1M | -$13.5M | -$45.9M | -$31.9M | ···· | ···· | ···· | ···· | ···· |
| Operating Income | -$23.5M | -$18.4M | -$35.7M | -$30.5M | ···· | ···· | ···· | ···· | ···· |
| Interest Expense | -$3.5M | -$387K | $4.8M | $5.8M | ···· | ···· | ···· | ···· | ···· |
| Income Before Tax | -$22.4M | -$15.9M | -$54.1M | -$41.2M | ···· | ···· | ···· | ···· | ···· |
| Income Tax Expense | $75K | $13K | $7K | $28K | ···· | ···· | ···· | ···· | ···· |
| Net Income | $51.8M | $53.4M | -$53.9M | -$37.7M | ···· | ···· | ···· | ···· | ···· |
| Basic EPS | $1.30 | $1.29 | $-1.86 | $-2.07 | ···· | ···· | ···· | ···· | ···· |
| Basic Shares | 43.62M | 41.42M | 29.07M | 18.16M | ···· | ···· | ···· | ···· | ···· |
| Diluted Shares | 43.62M | 45.94M | 29.07M | 18.16M | ···· | ···· | ···· | ···· | ···· |
Earnings Summary
Revenue
$2.4M
Estimate unavailable.
Revenue Beat/Miss
Not available (no estimate stored)
EPS
-$0.18
Estimate unavailable.
EPS Beat/Miss
Not available (no estimate stored)
Debt Change
-61.8%
Cash Change
+134.1%
Margin Change
-161.6 pp
Debt and cash show percentage changes versus the comparison period; margin shows the change in percentage points (pp). These are company-wide changes, not per-share amounts.
Financial Changes Since Prior Period
What Improved
- Cash position grew
- Debt reduced
What Weakened
- Margins contracted
Potential Score Impact
Positive indicators included cash levels, debt levels. Pressure indicators included revenue growth, EPS growth, net income margin. These factors may support or pressure the Revenue, Management, Financial, and Debt categories; this summary does not claim that the stored scores changed.
Stored Earnings Analysis
Revenue declined 61.2%. EPS declined 30.8%. Cash increased 134.1%. Total debt declined 61.8%. Net income margin declined by 161.6 percentage points.
Earnings-Call Transcript
Earnings-call transcript analysis is not currently available.
These results may influence future scores when the next evaluation is completed.
Insider Activity
Guru / Smart Money
Guru Score
Smart Money
Number of Gurus
Total Guru Value
Avg Portfolio Weight
Largest Holder
Largest Holder %
New Positions
Increased Positions
Reduced Positions
Exited Positions
Net Guru Sentiment
Short Interest
Dividend History
Dividend data is not available yet. Missing data does not mean this company pays no dividend.
Conservative Projected Values
3 Years
$———.——
5 Years
$———.——
10 Years
$———.——
Conservative Projection Rate
——%
Conservative Projected Values — price projections derived from actual 10-year adjusted historical returns, conservatively adjusted and capped at 8% annually. These are distinct from the Outperformance Model Score and WallStreetScore.
Conservative Projected Values
Premium unlocks the 3-year, 5-year, and 10-year conservative projected values with full calculation breakdowns based on actual historical returns.
Start 7-Day Free TrialHistorical Outperformance Record
Premium includes stored forecasts and any available evaluated results. Completed results, win rates and calibrated probabilities are shown only when supported records exist; access does not create historical outcomes.
Start 7-Day Free TrialHistorical Trends
6 historical recordsHistorical Score Chart
3 of 6 records shownWall Street Score
Debt Score
Revenue Score
Asset Score
Capital Score
Management Score
Moat Score
Valuation Score
Buffett Score
Intrinsic Value
Value Reference
Margin of Safety %
Related Companies
BiotechnologyNews
Financial Analysis: Elutia (NASDAQ:ELUT) & QuidelOrtho (NASDAQ:QDEL)
Elutia to Present at the H.C. Wainwright 28th Annual Global Investment Conference on September 15th
Jushi (OTCMKTS:JUSHF) vs. Elutia (NASDAQ:ELUT) Head-To-Head Survey
Elutia to Participate in the Lake Street Capital Markets 10th Annual Big Ideas Growth Conference & the H.C. Wainwright 28th Annual Global Investment Conference
Rumor Mill · ELUT
Corporate developments & opportunities
No reviewed developments match this filter.
Evidence credibility is not a forecast of stock performance. Rumor Mill is separate from the WSS score.
Related Stock Research
Continue researching this company with related Wall Street Score rankings and investing guides.
Score Alerts
Premium unlocks alerts when a score rises, falls, or reaches your target price.
Start 7-Day Free TrialPortfolio Score
Premium unlocks portfolio scoring, strongest and weakest holdings, and overall margin of safety.
Start 7-Day Free Trial